Novel fusion peptide-mediated siRNA delivery using self-assembled nanocomplex

Background: Gene silencing using siRNA can be a new potent strategy to treat many incurable diseases at the genetic level, including cancer and viral infections. Treatments using siRNA essentially requires an efficient and safe method of delivering siRNA into cells while maintaining its stability. Thus, we designed novel synergistic fusion peptides, i.e., SPACE and oligoarginine. Results: Among the novel fusion peptides and siRNAs, nanocomplexes have enhanced cellular uptake and gene silencing effect in vitro and improved retention and gene silencing effects of siRNAs in vivo. Oligoarginine could attract siRNAs electrostatically to form stable and self-assembled nanocomplexes, and the SPACE peptide could interact with the cellular membrane via hydrogen bonding. Therefore, nanocomplexes using fusion peptides showed improved and evident cellular uptake and gene silencing of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) via the lipid raft-mediated endocytosis pathway, especially to the HDFn cells of the skin, and all of the fusion peptides were biocompatible. Also, intratumorally injected nanocomplexes had increased retention time of siRNAs at the site of the tumor. Finally, nanocomplexes demonstrated significant in vivo gene silencing effect without overt tissue damage and immune cell infiltration. Conclusions: The new nanocomplex strategy could become a safe and efficient platform for the delivery of siRNAs [GRAPHICS] into cells and tissues to treat various target diseases through gene silencing.

Automated summary

Novel synergy fusion peptides SPACE and oligoarginine improved cellular uptake and gene silencing effect of siRNA in vitro, as well as retention and gene silencing effects of siRNAs in vivo. The nanocomplexes using fusion peptides showed enhanced cellular uptake and gene silencing effects via lipid raft-mediated endocytosis pathway, making them a potential safe and efficient platform for delivering siRNAs for gene silencing therapies.